High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Inclusion Criteria Subjects will be eligible if the following criteria are met: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age \> 21 years * History of a clinical diagnosis of radiation retinopathy * Subjects who are at least 3 months and no more than 10 years from radiation therapy * History of prior treatment for radiation retinopathy with incomplete response (eg. persistent edema, presence of hemorrhage, presence of exudates, etc * ETDRS best corrected visual acuity of 20/400 or better in the study eye * Ability to return for all study visits Exclusion Criteria Subjects who meet any of the following criteria will be excluded from this study: * Pregnancy (positive pregnancy test) or lactation Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch. * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial * Subject with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. * Subjects who have undergone intraocular surgery within last 60 days. * Subjects who have had intravitreal anti-VEGF treatment within 30 days. * Subjects who have had intravitreal triamcinolone acetonide within 4 months. * Subjects who have had laser within 60 days. * Inability to obtain photographs to document CNV (including difficulty with venous access). * Subject with known adverse reaction to fluorescein dye. * Subject has a history of any medical condition which would preclude scheduled visits or completion of study. * Aphakia or absence of the posterior capsule in the study eye. Previous violation of the posterior capsule in the study eye is also excluded unless as a result of yttrium aluminum garnet (YAG) posterior capsulotomy in association with posterior chamber lens implantation.. * History of glaucoma filtering surgery in the study eye. * Concurrent use of more than two therapies for glaucoma. * Uncontrolled glaucoma in the study eye (defined as intraocular pressure \>30 mm Hg despite treatment with anti-glaucoma medication) * Inability to comply with study or follow-up procedure